Barcelona, April 30th, 2019
We are pleased to announce that Labiana Life Sciences S.A. has signed an agreement to acquire majority shareholding in Zoleant Pharmaceuticals International.
Since its founding in 1958, Labiana Group has undergone continuous evolution from being a company of nutritionals to becoming a modern and competitive company that is currently offering a wide range of Contract Development and Manufacturing services as well as proprietary animal health and human medicine products.
Labiana Group has a main office in Madrid and Barcelone and two manufacturing plants, one in Corbera de Llobregat (Human Health) and another one Terrassa (Animal Health), both of them very close to Barcelona. With its workforce of more than 320 professionals, Labiana Group is present worldwide with approximately 400 marketing authorizations in more than 50 export markets in the AEMEA regions (Africa, Europe, the Middle East and Asia) and Latin America.
With Labiana’s ambition to become a global niche player in the animal health industry, Manuel Ramos Ortega, CEO of Labiana Group, said “We think that this transaction is an appropriate catalyst to reach our goals because of Zoleant´s strategic positioning, market access and product portfolio, all of which are complementary and strategic for us in the MENA region. We also see an opportunity to become a regional trusted partner and to formalize and expand our commercial relationship through new acquisitions to encompass new holistic solutions for our customers whatever market and species they have focused on.”
Established in 2016 by Burak Kutal, Dr. Suha Mirac Kaya and the investment party Vona International, Zoleant Pharmaceuticals International quickly developed its sales network and emerged into a global brand. Nowadays, Zoleant’s expanding international presence spans from West to East entailing 11 countries with its strategically selected manufacturing partners in Europe, Turkey and Asia.
“Labiana’s history, expertise, manufacturing and laboratory capabilities coupled with a vast global commercial reach, provides a tremendous opportunity for Zoleant to serve distributors and wholesalers of veterinarian products in the region as its key business partner”, reported Burak Kutal, CEO of Zoleant Pharmaceuticals.
This transaction will bring an emerging capacity for innovation, a superior customer experience and a regional commercial acceleration within a highly competitive and dynamic market. We are confident that this merger will deliver maximum value to our current and future partners (both in distribution and in the supply chain).
We look forward to growing together while continuing to create a beneficial environment for all.